RNAC - Cartesian Therapeutics Inc.

RNAC - Cartesian Therapeutics Inc.

https://www.cartesiantherapeutics.com

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

Cartesian Therapeutics to Participate in Upcoming Investor Conferences - Cartesian Therapeutics ( NASDAQ:RNAC )

Benzinga • 2 weeks, 4 days ago • score: 0.12

FREDERICK, Md., Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Cartesian Therapeutics, Inc. RNAC ( the "Company" ) , a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in ...

Cartesian Therapeutics Announces New Employment Inducement Grants

GlobeNewswire • 1 month, 1 week ago • score: 0.30

FREDERICK, Md., Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- Cartesian Therapeutics, Inc. ( NASDAQ: RNAC ) ( the "Company" ) , a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees.

Cartesian Therapeutics Announces New Employment Inducement Grants - Cartesian Therapeutics ( NASDAQ:RNAC )

Benzinga • 1 month, 1 week ago • score: 0.24

FREDERICK, Md., Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- Cartesian Therapeutics, Inc. RNAC ( the "Company" ) , a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees.

Cartesian Therapeutics, Inc. ( RNAC ) Moves 9.9% Higher: Will This Strength Last?

Zacks Commentary • 1 month, 3 weeks ago • score: 0.40

Cartesian Therapeutics, Inc. (RNAC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Exelixis ( EXEL ) Surges 7.4%: Is This an Indication of Further Gains?

Zacks Commentary • 2 months, 3 weeks ago

Exelixis (EXEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Cartesian Therapeutics Announces New Employment Inducement Grants

GlobeNewswire • 3 months, 1 week ago • score: 0.30

FREDERICK, Md., June 03, 2025 ( GLOBE NEWSWIRE ) -- Cartesian Therapeutics, Inc. ( NASDAQ: RNAC ) ( the "Company" ) , a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to three new employees.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-10 (Snapshot)

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company is headquartered in Watertown, Massachusetts.

52W High

$26.50

52W Low

$8.46

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.83

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

25.45

EV/EBITDA (<8 favorable)

-1.17

EV/Revenue (<3 favorable)

126.40

P/S (TTM) (<3 favorable)

269.65

P/B (<3 favorable)

31.26

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

59.85%

Institutions (25–75% balanced)

25.41%

Shares Outstanding

26,002,000

Float

9,390,400

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

1,026,000

Gross Profit (TTM)

-45,476,000

EPS (TTM)

-0.68

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-73.19%

ROE (TTM) (>15% strong)

-70.29%

EPS YoY (Quarterly) (>10% good)

-0.07

Revenue YoY (Quarterly) (>8% good)

-0.99

Momentum

Bearish momentum

Value

-0.5026

Previous

-0.5665

Trend

Rising

Signal Cross

No cross

As of

Sep. 05, 2025